Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two-Week Outcomes.

Clin Ophthalmol · 2022 · PMC9793787 · PMID 36583092

Europe PMC DOI

hedged sentence

0.4490

closest p · 9.0× alpha

0.4490

boldest claim

The sentences

did not reach statistical significanceP =0.449not close (p > 0.1)

Subgroup analysis revealed a similar significant improvement in BCVA in the switch therapy groups (Baseline median BCVA: 0.8 [0.53–1.23] logMAR; Final median BCVA: 0.6 [0.38–1] logMAR; P <0.001) while the improvement in treatment-naïve eyes did not reach statistical significance (Baseline median BCVA: 0.3 [0.17–0.53] logMAR; Final median BCVA: 0.17 [0.17–0.3] logMAR; P =0.449).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.